Beta2-adrenergic Agonism and Muscle Remodelling

Gender-specific Role of the beta2-adrenergic Stimulation With Short- or Long-acting Selective Agonist in Relation to Muscle Remodelling, Function, Performance, and Anti-doping

Status

UNKNOWN

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT03565302

Enrollment

Registered

2018-06-21

Start date

2018-06-25

Completion date

2021-05-30

Last updated

2020-03-25

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hypertrophy, Physical Activity, Physiologic Hypertrophy

Keywords

Proteome, VO2max, Muscle function, Exercise performance, Skeletal muscle, Doping, Anti-Doping, Enantiomeric analysis

Brief summary

The study aims to investigate gender-specific adaptations to beta2-adrenoceptor stimulation with selective short- and long-acting beta2-agonist with emphasis on skeletal muscle in relation to performance enhancing effects and anti-doping

Interventions

DRUGFormoterol

Subjects are treated with daily inhalation of formoterol

DRUGTerbutaline

Subjects are treated with daily inhalation of terbutaline

OTHERPlacebo

Subjects are treated with placebo

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

BASIC_SCIENCE

Masking

TRIPLE (Subject, Investigator, Outcomes Assessor)

Eligibility

Sex/Gender

ALL

Age

18 Years to 45 Years

Healthy volunteers

Yes

Inclusion criteria

* Healthy men and women, aged 18-45 years * VO2max \>55 ml/kg/min for men and \>50 ml/kg/min for women (± biologic and techinical variation of 5.6% (Katch et al. 1982) * Body Mass Index (BMI) \< 26

Exclusion criteria

* Chronic user of beta2-agonist or allergy towards study drugs * Serious adverse side effects of the used study drug * Chronic disease that by the project physician would affect any of the outcomes of the study * Smoker * Chronic use of prescription medication (other than contraceptives for women) * Pregnancy

Design outcomes

Primary

Measure	Time frame	Description
Proteome enrichment	Baseline and 6 weeks	Change in enrichment (measured in muscle biopsies and assessed using GO annotations)

Secondary

Measure	Time frame	Description
Body composition	Baseline, 2 weeks, 4 weeks and 6 weeks	Change in body composition (measured by dual energy x ray absorptiometry)
Maximal oxygen consumption (VO2max)	Baseline, 2 weeks, 4 weeks and 6 weeks	Change in VO2max (measured during bike ergometer cycling to exhaustion)

Other

Measure	Time frame	Description
Drug exposure	Day 1-14 and day 49-56	Measured in urine using enantiomeric analysis

Countries

Denmark

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026